Medicus Pharma Q3 EPS Decreased by Brookline Capital Markets

Medicus Pharma Ltd (NASDAQ:MDCX) – Investment analysts at Brookline Capital Markets reduced their Q3 2026 earnings estimates for shares of Medicus Pharma in a research report issued to clients and investors on Friday, August 14th. Brookline Capital Markets analyst K. Raja now expects that the company will post earnings of ($0.16) per share for the quarter, down from their prior estimate of ($0.09). The consensus estimate for Medicus Pharma’s current full-year earnings is ($0.51) per share. Brookline Capital Markets also issued estimates for Medicus Pharma’s Q4 2026 earnings at ($0.11) EPS, FY2026 earnings at ($0.67) EPS, FY2027 earnings at ($0.59) EPS and FY2028 earnings at ($0.54) EPS.

Medicus Pharma (NASDAQ:MDCX) last posted its quarterly earnings data on Wednesday, August 12th. The company reported ($0.21) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.13) by ($0.08).

Other analysts also recently issued reports about the company. Roth Capital assumed coverage on Medicus Pharma in a research note on Tuesday, April 21st. They set a “buy” rating for the company. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Medicus Pharma in a research note on Wednesday, July 8th. D. Boral Capital reiterated a “buy” rating and set a $9.00 target price on shares of Medicus Pharma in a report on Monday, April 20th. Finally, Alliance Global Partners restated a “buy” rating on shares of Medicus Pharma in a report on Monday. Three analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $9.00.

Medicus Pharma Trading Down 7.2%

Shares of NASDAQ:MDCX opened at $0.26 on Tuesday. Medicus Pharma has a twelve month low of $0.25 and a twelve month high of $3.05. The company has a market capitalization of $16.43 million, a PE ratio of -0.11 and a beta of 0.11. The firm has a 50 day simple moving average of $0.37 and a 200-day simple moving average of $0.53.

Institutional Investors Weigh In On Medicus Pharma

Several institutional investors and hedge funds have recently bought and sold shares of MDCX. HRT Financial LP bought a new position in shares of Medicus Pharma during the fourth quarter valued at approximately $42,000. Wilmington Savings Fund Society FSB increased its position in Medicus Pharma by 100.0% in the fourth quarter. Wilmington Savings Fund Society FSB now owns 51,244 shares of the company’s stock worth $78,000 after buying an additional 25,622 shares during the period. Armistice Capital LLC acquired a new stake in Medicus Pharma in the fourth quarter worth $2,771,000. Private Advisor Group LLC lifted its stake in Medicus Pharma by 3.8% in the third quarter. Private Advisor Group LLC now owns 151,500 shares of the company’s stock valued at $351,000 after buying an additional 5,500 shares during the last quarter. Finally, Jane Street Group LLC bought a new position in shares of Medicus Pharma during the fourth quarter worth about $92,000.

Medicus Pharma Company Profile

Medicus Pharma, Inc, traded on the Nasdaq under the ticker MDCX, is a specialty pharmaceutical company focused on the development, acquisition and commercialization of prescription therapies. The company’s core business centers on oncology supportive care and critical care products, with its lead offering being Levoleucovorin injection, an FDA-approved agent designed to reduce toxicity and enhance efficacy of certain chemotherapeutic regimens in colorectal cancer.

Headquartered in the United States, Medicus Pharma has built its portfolio through strategic licensing and acquisition of sterile injectable and oral therapies.